IP Verse

Use Of Pilocarpine Hydrochloride For The Treatment Of Ocular Conditions - EP3681500

The patent EP3681500 was granted to Allergan on Jul 30, 2025. The application was originally filed on Apr 24, 2019 under application number EP19729883A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3681500

ALLERGAN
Application Number
EP19729883A
Filing Date
Apr 24, 2019
Status
Patent Maintained As Amended
Jun 27, 2025
Grant Date
Jul 30, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSDec 20, 2022KRAUS & LEDERER PARTGMBBWITHDRAWN

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS5424078
EXAMINATIONEP1938839
INTERNATIONAL-SEARCH-REPORTEP1938839
INTERNATIONAL-SEARCH-REPORTEP2886113
INTERNATIONAL-SEARCH-REPORTUS2005205101
INTERNATIONAL-SEARCH-REPORTWO0064425
OPPOSITIONWO0006135

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- ABRAMSON D. H., FRANZEN L. A., COLEMAN D. J., "PILOCARPINE IN THE PRESBYOPE. DEMONSTRATION OF AN EFFECT ON THE ANTERIOR CHAMBER AND LENS THICKNESS.", Archives of Ophthalmology, United States , (19730201), vol. 89, no. 2, ISSN 0003-9950, pages 100 - 102, XP000866126
OPPOSITION- "A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia", History of Changes for Study: NCT02780115, (20171115), URL: https://clinicaltrials.gov/ct2/history/NCT02780115?V_6=View#StudyPageTop, XP093012594
OPPOSITION- "A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia", History of Changes for Study: NCT02595528, (20171031), URL: https://clinicaltrials.gov/ct2/history/NCT02595528?V_9=View#StudyPageTop, XP093012589
OPPOSITION- Bartlett Jimmy D., Jaanus Siret D., Clinical Ocular Pharmacology, 5th ed., (20080101), pages 27 - 37, XP093012618
OPPOSITION- Brown H.S. et al, "Visual effects of pilocarpine in glaucoma comparative study of administration by eyedrops or by ocular therapeutic systems.", Archives of Ophthalmology, American Medical Association, United States, United States , (19761001), vol. 94, no. 10, ISSN 0003-9950, pages 1716 - 1719, XP009090432
OPPOSITION- "Isopto® Carpine (pilocarpine hydrocloride opthalmic solution) 1%, 2% and 4%", Highlights of Prescribing Information, (20100601), pages 1 - 5, XP093012370
OPPOSITION- Kevin K. Ma, Jennifer Rose-Nussbaumer, "Clinical Trial Design - The Best Approach Is Often the Simple One", JAMA Opthalmology, (20220401), vol. 140, no. 4, pages 371 - 372, XP093012651
OPPOSITION- Levin Leonard A., Nilsson Siv F E, Ver Hoeve James, Wu Samuel M, Kaufman Paul L, Alm Albert, ADLER'S PHYSIOLOGY OF THE EYE, 11th ed., (20110101), pages 40 - 70, XP093012614
OPPOSITION- "Pilocarpine Eye Drops 1%, 2% and 4% w/v", Package Leaflet Information for User, (20160401), pages 1 - 2, XP093012581
OPPOSITION- Price Francis W. et al, "Combinations of Pilocarpine and Oxymetazoline for the Pharmacological Treatment of Presbyopia", AMERICAN ACADEMY OF OPHTHALMOLOGY, (20210101), pages 1 - 13, XP093228777
OPPOSITION- "Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia", History of Changes for Study: NCT02197806, (20151030), URL: https://clinicaltrials.gov/ct2/history/NCT02197806?V_4=View#StudyPageTop, XP093012584
OPPOSITION- Thom J. Zimmerman, Thomas M. Wheeler, "Miotics - Side Effects and Ways to Avoid Them", Ophthalmology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (19820101), vol. 89, no. 1, doi:10.1016/S0161-6420(82)34866-6, ISSN 0161-6420, pages 76 - 80, XP009550725
OPPOSITION- Schehlein Emily M., Novack Gary, Robin Alan L., "New pharmacotherapy for the treatment of glaucoma", Expert Opin Pharmacother, Ashley Publications LTD, London, UK, London, UK , (20171212), vol. 18, no. 18, doi:10.1080/14656566.2017.1408791, ISSN 1465-6566, pages 1939 - 1946, XP093112397
OPPOSITION- Meseguer Georges, Buri Pierre, Plazonnet Bernard, Rozier Annouk, Gurny Robert, "Gamma Scintigraphic Comparison of Eyedrops Containing Pilocarpine in Healthy Volunteers", Journal of Ocular Pharmacology and Therapeutics, US , (19960101), vol. 12, no. 4, doi:10.1089/jop.1996.12.481, ISSN 1080-7683, pages 481 - 488, XP093012607
OPPOSITION- Westheimer Gerald, "Topical Review: Pilocarpine-induced Miosis as Help for Early Presbyopes?", Optom. Vis. Sci., (20220101), vol. 99, no. 8, doi:10.1097/OPX.0000000000001924, pages 632 - 634, XP093012633

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents